1. | BuyHighSellLow | |
2. | vivmawhinney | |
3. | liviukq0jcynvi | |
4. | peterholmbeck | |
5. | ca7946jguen |
1. | BuyHighSellLow | |
2. | vivmawhinney | |
3. | liviukq0jcynvi | |
4. | peterholmbeck | |
5. | ca7946jguen |
1. | vivmawhinney 02/21/2018 Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and Betrixaban |
2. | BuyHighSellLow 02/20/2018 positive trend vote |
3. | vivmawhinney 02/28/2018 Shares under pressure on reports the FDA may require additional data for Andexxa. |
4. | vivmawhinney 05/04/2018 Rally on! Here's Why Portola Pharmaceuticals (PTLA) Shares Jumped 20% Today |
5. | liviukq0jcynvi 02/21/2018 Credit Suisse reiterates Outperform rating; PT lowered to $53 from $68 |
6. | BuyHighSellLow 02/28/2018 Carnage |
7. | BuyHighSellLow 05/24/2018 Portola Pharmaceuticals Receives $100 Million Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa® |
8. | liviukq0jcynvi 03/01/2018 Portola Pharmaceuticals Inc (PTLA): Oppenheimer Lowers Price Target Amid Apprehension Circling AndexXa's Approval Timeline |
9. | liviukq0jcynvi 02/21/2018 Drivel. |
10. | peterholmbeck 03/26/2018 Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union |